Reinhardt, Lars

[["dc.bibliographiccitation.artnumber","260"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","BMC Research Notes"],["dc.bibliographiccitation.volume","8"],["dc.contributor.author","Mechie, Nicolae-Catalin"],["dc.contributor.author","Goralzcyk, Armin D."],["dc.contributor.author","Reinhardt, Lars"],["dc.contributor.author","Mihm, Sabine"],["dc.contributor.author","Amanzada, Ahmad"],["dc.date.accessioned","2019-07-09T11:41:45Z"],["dc.date.available","2019-07-09T11:41:45Z"],["dc.date.issued","2015"],["dc.description.abstract","Background Chronic hepatitis C (CHC) is a global health challenge. New therapeutic agents with excellent sustained virological response (SVR) rates are available mainly in developed countries, while the majority of CHC patients live in countries with low health budget. Predictors of therapeutic response are therefore necessary. Vitamin B12 appears to be involved in hepatitis C virus replication. Methods We therefore studied retrospectively the relationship between baseline serum vitamin B12 levels and clinical features in 116 CHC genotype 1 infected patients. Logistic regression models with univariate and multivariate analysis were used in the statistical analysis. Results Baseline serum vitamin B12 levels were found to be positively associated with serum transaminase activities (AST, p = 0.002, ALT, p = 0.04), baseline viral load (p < 0.0001), stage of fibrosis (p = 0.0001) and favorable interferon-λ3/4 (IFNL3/IFNL4) rs12979860 genotypes (p = 0.04), and inversely with SVR (p < 0.001) as well as with rapid virological response (p = 0.001). Patients with baseline serum vitamin B12 levels below a cut-off value of 570 ng/L achieved a SVR rate of 59% with an odds ratio (OR) of 13.4 [confidence interval (CI) 4.3–41.9, p < 0.0001] compared to patients above the cut-off value. By combining serum vitamin B12 levels and IFNL3/IFNL4 rs12979860 genotypes, patients with baseline serum vitamin B12 levels below the cut-off value of 570 ng/L and IFNL3/IFNL4 rs12979860 CC genotype achieved a SVR rate of even 80% with an OR of 54 (CI 9.9–293, p < 0.0001) compared to patients above the cut-off value and non-CC-genotypes. Conclusion Our data suggest baseline serum vitamin B12 levels as useful noninvasive marker for characterizing CHC patients. They might further help to identify responders to a standard treatment."],["dc.identifier.doi","10.1186/s13104-015-1248-z"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/12298"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/58502"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Association of serum vitamin B12 levels with stage of liver fibrosis and treatment outcome in patients with chronic hepatitis C virus genotype 1 infection: a retrospective study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Journal of Hepatology"],["dc.bibliographiccitation.volume","56"],["dc.contributor.author","Amanzada, Ahmad"],["dc.contributor.author","Schneider, S."],["dc.contributor.author","Lindhorst, Alexander"],["dc.contributor.author","Moriconi, Federico"],["dc.contributor.author","Reinhardt, Lars"],["dc.contributor.author","Wietzke-Braun, Perdita"],["dc.contributor.author","Mihm, Sabine"],["dc.contributor.author","Ramadori, Giuliano"],["dc.date.accessioned","2018-11-07T09:11:32Z"],["dc.date.available","2018-11-07T09:11:32Z"],["dc.date.issued","2012"],["dc.format.extent","S426"],["dc.identifier.isi","000303241302190"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/26741"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Bv"],["dc.publisher.place","Amsterdam"],["dc.relation.conference","47th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL)"],["dc.relation.eventlocation","Barcelona, SPAIN"],["dc.relation.issn","0168-8278"],["dc.title","RATHER THE ALLELIC VARIATION OF IL28B BUT NOT OF CYP27B1 OR HCV GENOTYPE PREDICT SPONTANEOUS ELIMINATION OF HCV-INFECTION"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Journal of Hepatology"],["dc.bibliographiccitation.volume","56"],["dc.contributor.author","Amanzada, Ahmad"],["dc.contributor.author","Schneider, S."],["dc.contributor.author","Lindhorst, Alexander"],["dc.contributor.author","Moriconi, Federico"],["dc.contributor.author","Reinhardt, Lars"],["dc.contributor.author","Ramadori, Giuliano"],["dc.date.accessioned","2018-11-07T09:11:31Z"],["dc.date.available","2018-11-07T09:11:31Z"],["dc.date.issued","2012"],["dc.format.extent","S426"],["dc.identifier.isi","000303241302191"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/26740"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Bv"],["dc.publisher.place","Amsterdam"],["dc.relation.conference","47th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL)"],["dc.relation.eventlocation","Barcelona, SPAIN"],["dc.relation.issn","0168-8278"],["dc.title","CHRONIC AND PROGRESSIVE HEPATITIS DUE TO GENOTYPE 1 HCV-INFECTION MODIFY VITAMIN-D-METABOLISM"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","503"],["dc.bibliographiccitation.journal","BMC Infectious Diseases"],["dc.bibliographiccitation.volume","14"],["dc.contributor.author","Amanzada, Ahmad"],["dc.contributor.author","Goralczyk, Armin Dietmar"],["dc.contributor.author","Reinhardt, Lars"],["dc.contributor.author","Moriconi, Federico"],["dc.contributor.author","Cameron, Silke"],["dc.contributor.author","Mihm, Sabine"],["dc.date.accessioned","2018-11-07T09:35:10Z"],["dc.date.available","2018-11-07T09:35:10Z"],["dc.date.issued","2014"],["dc.description.abstract","Background: A decline in hemoglobin (Hb) concentration during antiviral therapy in chronic hepatitis C (CHC) is a serious side effect. It may compel to dose reduction or even termination of antiviral treatment. The activation of erythropoietin (EPO) synthesis as a physiological response to anemia and its relation to a genetic variation within the EPO gene has not been evaluated yet. Methods: Data of 348 CHC patients were reviewed retrospectively. Samples were genotyped for EPO rs1617640 and inosine triphosphatase (ITPA) rs1127354. Serum EPO concentrations were determined before and during therapy. Primary endpoints were set as Hb decline > 3 g/dl at weeks 4 and 12. Results: EPO rs1617640 G homozygotes showed a significantly lower rise of serum EPO level over time than T allele carriers (p < 0.001). The cumulative frequency of a significant Hb reduction added up to 40%. Multivariate analysis revealed that besides age, ribavirin starting dose and baseline Hb also EPO rs1617640 G homozygosity associates with Hb reduction at week 4 (p = 0.025) and 12 (p = 0.029), while ITPA C homozygotes are at risk for Hb decline particularly early during treatment. Furthermore, EPO rs1617640 G homozygotes were more frequently in need for blood transfusion, epoetin-a supplementation, or ribavirin dose reduction (p < 0.001). Conclusions: Our data suggest that EPO rs1617640 genotype, the rise of serum EPO concentration as well as ITPA rs1127354 genotype are promising parameters to evaluate the Hb decline during antiviral therapy. A rational adjustment of therapy with epoetin-a supplementation might prevent serious adverse events or the need to terminate treatment."],["dc.identifier.doi","10.1186/1471-2334-14-503"],["dc.identifier.isi","000341954900001"],["dc.identifier.pmid","25227310"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/32330"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Biomed Central Ltd"],["dc.relation.issn","1471-2334"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Erythropoietin rs1617640 G allele associates with an attenuated rise of serum erythropoietin and a marked decline of hemoglobin in hepatitis C patients undergoing antiviral therapy"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2188"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","Stroke"],["dc.bibliographiccitation.lastpage","2193"],["dc.bibliographiccitation.volume","44"],["dc.contributor.author","Psychogios, M.-N."],["dc.contributor.author","Schramm, P."],["dc.contributor.author","Frolich, A. M."],["dc.contributor.author","Kallenberg, K."],["dc.contributor.author","Wasser, K."],["dc.contributor.author","Reinhardt, L."],["dc.contributor.author","Kreusch, A. S."],["dc.contributor.author","Jung, K."],["dc.contributor.author","Knauth, M."],["dc.date.accessioned","2021-06-01T10:47:49Z"],["dc.date.available","2021-06-01T10:47:49Z"],["dc.date.issued","2013"],["dc.identifier.doi","10.1161/STROKEAHA.113.001068"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/85730"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.relation.eissn","1524-4628"],["dc.relation.issn","0039-2499"],["dc.title","Alberta Stroke Program Early CT Scale Evaluation of Multimodal Computed Tomography in Predicting Clinical Outcomes of Stroke Patients Treated With Aspiration Thrombectomy"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Der Internist"],["dc.bibliographiccitation.volume","58"],["dc.contributor.author","Reinhardt, Lars"],["dc.contributor.author","Eiffert, Helmut"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Stroebel, Philipp"],["dc.contributor.author","Bremer, S. C. B."],["dc.contributor.author","Amanzada, Ahmad"],["dc.contributor.author","Ellenrieder, Volker"],["dc.contributor.author","Neesse, A."],["dc.date.accessioned","2018-11-07T10:23:13Z"],["dc.date.available","2018-11-07T10:23:13Z"],["dc.date.issued","2017"],["dc.format.extent","626"],["dc.identifier.doi","10.1007/s00108-017-0228-x"],["dc.identifier.isi","000402791100013"],["dc.identifier.pmid","28389763"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/42417"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Springer"],["dc.relation.issn","1432-1289"],["dc.relation.issn","0020-9554"],["dc.title","Spontaneous Remission of HCV Infection after autologous Stem Cell Transplantation in a 58-year-old Man (vol 58, pg 626, 2017)"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","219"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Notfall + Rettungsmedizin"],["dc.bibliographiccitation.lastpage","226"],["dc.bibliographiccitation.volume","13"],["dc.contributor.author","Reinhardt, Lars"],["dc.contributor.author","Bahr, Jan"],["dc.contributor.author","Schmid, Oliver"],["dc.contributor.author","Kettler, Dietrich"],["dc.contributor.author","Roessler, M."],["dc.date.accessioned","2018-11-07T08:43:44Z"],["dc.date.available","2018-11-07T08:43:44Z"],["dc.date.issued","2010"],["dc.description.abstract","Despite all progress in modern medicine, cardiovascular diseases and sudden cardiac death remain one of the most frequent causes of death worldwide. As most of these cases are caused by ventricular fibrillation which rapidly reduces the chances of survival and can only be terminated by defibrillation, inclusion of lay rescuers to perform basic life support and use automated external defibrillators (AED) within a public access defibrillation program according to the latest recommendations of the European Resuscitation Council (ERC) and the American Heart Association (AHA) has become a milestone in combating sudden cardiac death. Nevertheless, correct AED placement is still a problem and implementing a public access defibrillation (PAD) program is still a challenge. Therefore, performing needs assessment should be the first step in identifying suitable sites for placement of AEDs. The Gottingen AED model provides a tool for such a needs assessment. However, this model certainly needs further validation."],["dc.identifier.doi","10.1007/s10049-010-1311-1"],["dc.identifier.isi","000277146400006"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/20041"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","1434-6222"],["dc.title","The Gottingen AED model"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e0143783"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","PLoS ONE"],["dc.bibliographiccitation.volume","10"],["dc.contributor.author","Amanzada, Ahmad"],["dc.contributor.author","Reinhardt, Lars"],["dc.contributor.author","Fey, Dorothea"],["dc.contributor.author","Zeisberg, Elisabeth M."],["dc.contributor.author","Mihm, Sabine"],["dc.date.accessioned","2018-11-07T09:48:47Z"],["dc.date.available","2018-11-07T09:48:47Z"],["dc.date.issued","2015"],["dc.description.abstract","Genetic polymorphisms in the region of the interferon-lambda genes (IFNL) associate with clearance of hepatitis C virus (HCV) infection. One of these polymorphisms, IFNL4 rs368234815, determines loss or gain of function of the IFNL4 gene by frameshift variation. The very same and a second one, IFNL3 rs4803217, are supposed to impact the expression of IFNL3: while IFNL4 rs368234815 is suggested to modulate IFNL3 transcription, IFNL3 rs4803217 is thought to alter IFNL3 mRNA stability. The latter process is believed to be partially driven by an HCV-induced ectopic expression of myosin heavy chain genes 7B and 7 and their coexpressed microRNAs mir499 and mir208B. These ideas are evidenced by functional investigations on peripheral blood mononuclear and hepatoma cells in culture. Our study aimed at exploring IFNL3 gene expression in clinical samples, i.e., in ex vivo derived liver tissue from patients with chronic hepatitis C (n = 57) and various other diseases (n = 56). By applying an assay designed to specifically quantify IFNL3 and discriminating paralogous IFNL2 transcripts, IFNL3 mRNA expression was not found to differ significantly between chronic hepatitis C and control samples. Among patients with chronic HCV infection, moreover, IFNL3 rs4803217 or IFNL4 rs368234815 minor alleles did not associate with reduced IFNL3 gene expression. Finally, myosin heavy chain genes 7B and 7 and corresponding microRNAs mir499 and mir208B were not found activated in liver in chronic HCV infection. Of note, detectability of MYH7 mRNA related to the procedure of liver biopsy sampling, as tissue obtained by direct punctation of the liver during laparoscopic inspection was less likely to contain MYH7 transcripts than samples acquired by percutaneous punctation. In conclusion, data on ex vivo derived liver tissue samples argue against an attenuating impact of IFNL3 rs4803217 or IFNL4 rs368234815 minor alleles on hepatic IFNL3 gene expression in vivo."],["dc.description.sponsorship","Deutsche Forschungsgemeinschaft (DFG) [MI 474/1-1]"],["dc.description.sponsorship","Open-Access Publikationsfonds 2015"],["dc.identifier.doi","10.1371/journal.pone.0143783"],["dc.identifier.isi","000365865300111"],["dc.identifier.pmid","26606750"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/12614"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/35377"],["dc.identifier.url","https://sfb1002.med.uni-goettingen.de/production/literature/publications/139"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.relation","SFB 1002: Modulatorische Einheiten bei Herzinsuffizienz"],["dc.relation","SFB 1002 | C01: Epigenetische Kontrolle der Herzfibrose"],["dc.relation.issn","1932-6203"],["dc.relation.workinggroup","RG E. Zeisberg (Kardiales Stroma)"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Hepatic Interferon-lambda 3 (IFNL3) Gene Expression Reveals Not to Be Attenuated in Non-Favorable IFNL3 rs4803217 or IFNL4 rs368234815 Minor Allele Carriers in Chronic Hepatitis C"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original_ja"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","320"],["dc.bibliographiccitation.journal","Frontiers in Medicine"],["dc.bibliographiccitation.volume","5"],["dc.contributor.author","Bremer, Sebastian C. B."],["dc.contributor.author","Reinhardt, Lars"],["dc.contributor.author","Sobotta, Michael"],["dc.contributor.author","Hasselluhn, Marie C."],["dc.contributor.author","Lorf, Thomas"],["dc.contributor.author","Ellenrieder, Volker"],["dc.contributor.author","Schwörer, Harald"],["dc.date.accessioned","2019-07-09T11:49:36Z"],["dc.date.available","2019-07-09T11:49:36Z"],["dc.date.issued","2018"],["dc.description.abstract","Background: Liver transplant recipients are frequently treated with proton pump inhibitors. Drug interactions have been described especially with respect to omeprazole. Due to the lower binding capacity of pantoprazole to CYP2C19 this drug became preferred and became the most used proton pump inhibitor in Germany. The data on the influence of pantoprazole on immunosuppressive drugs in liver transplant recipients a very scarce. Methods: The authors performed a single center analysis in liver transplant recipients on the effect of pantoprazole on the serum trough levels of different immunosuppressants. The trough levels were compared over a period of 1 year before and after start or stop of a continuous oral co-administration of 40 mg pantoprazole once daily. Results: The serum trough levels of tacrolimus (n = 30), everolimus (n = 7), or sirolimus (n = 3) remain constant during an observation period of at least 1 year before and after co-administration of pantoprazole. None of the included patients needed a change of dosage of the observed immunosuppressants during the observation period. Conclusions: The oral co-administration of pantoprazole is safe in immunosuppressed liver transplant recipients according to the serum trough levels of tacrolimus, everolimus, and sirolimus. This analysis provides first data on the influence of pantoprazole on immunosuppressive drugs in liver transplant recipients."],["dc.identifier.doi","10.3389/fmed.2018.00320"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/15722"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/59589"],["dc.language.iso","en"],["dc.subject.ddc","610"],["dc.title","Pantoprazole Does not Affect Serum Trough Levels of Tacrolimus and Everolimus in Liver Transplant Recipients"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","621"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Der Internist"],["dc.bibliographiccitation.lastpage","625"],["dc.bibliographiccitation.volume","58"],["dc.contributor.author","Reinhardt, Lars"],["dc.contributor.author","Eiffert, Helmut"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Stroebel, Philipp"],["dc.contributor.author","Bremer, S. C. B."],["dc.contributor.author","Amanzada, Ahmad"],["dc.contributor.author","Ellenrieder, Volker"],["dc.contributor.author","Neesse, A."],["dc.date.accessioned","2018-11-07T10:23:13Z"],["dc.date.available","2018-11-07T10:23:13Z"],["dc.date.issued","2017"],["dc.description.abstract","We report about a 58-year-old man with a chronic and treatment-naive hepatitis C virus (HCV) infection of genotype 1b, who had undergone autologous stem cell transplantation twice due to multiple myeloma. Subsequently, a high-level viremic reactivation of an occult hepatitis B virus (HBV) infection and also a reverse seroconversion was observed. Furthermore, a sustained spontaneous remission of HCV infection was seen. Antiviral therapy of HBV infection was initiated with tenofovir. Seven months after therapy initiation, the patient acquired an \"anti-HBc-only\" status. Antiviral therapy with tenofovir is still continued. The patient is in a good clinical condition."],["dc.identifier.doi","10.1007/s00108-017-0206-3"],["dc.identifier.isi","000402791100012"],["dc.identifier.pmid","28235985"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/42415"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Springer"],["dc.relation.issn","1432-1289"],["dc.relation.issn","0020-9554"],["dc.title","Spontaneous remission of HCV infection after autologous stem cell transplantation in a 58-year-old man"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]